Seres Therapeutics, Inc. (MCRB) Receives Buy Rating from Seaport Global Securities

Seres Therapeutics, Inc. (NASDAQ:MCRB)‘s stock had its “buy” rating restated by Seaport Global Securities in a research report issued to clients and investors on Friday, MarketBeat reports. They currently have a $20.00 price target on the biotechnology company’s stock. Seaport Global Securities’ price objective would suggest a potential upside of 73.46% from the company’s previous close.

Other equities research analysts have also recently issued research reports about the company. BidaskClub cut Seres Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, August 11th. Cowen and Company reiterated a “buy” rating on shares of Seres Therapeutics in a report on Monday, October 2nd. Zacks Investment Research cut Seres Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, August 8th. HC Wainwright reiterated a “buy” rating and issued a $19.00 price objective (up previously from $15.00) on shares of Seres Therapeutics in a report on Friday, August 4th. Finally, Canaccord Genuity set a $20.00 price objective on Seres Therapeutics and gave the stock a “buy” rating in a report on Thursday, August 3rd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the stock. Seres Therapeutics presently has an average rating of “Buy” and an average price target of $17.50.

Shares of Seres Therapeutics (NASDAQ:MCRB) opened at 11.53 on Friday. The firm has a 50-day moving average price of $14.64 and a 200-day moving average price of $14.64. Seres Therapeutics has a one year low of $8.86 and a one year high of $17.42. The company’s market capitalization is $467.10 million.

Seres Therapeutics (NASDAQ:MCRB) last issued its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.10). The company had revenue of $3.00 million for the quarter, compared to analysts’ expectations of $3.00 million. Seres Therapeutics had a negative net margin of 441.38% and a negative return on equity of 80.21%. The company’s revenue was up .0% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.70) earnings per share. Equities analysts forecast that Seres Therapeutics will post ($2.55) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This piece of content was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this piece of content can be accessed at https://ledgergazette.com/2017/10/07/seres-therapeutics-inc-mcrb-receives-new-coverage-from-analysts-at-seaport-global-securities.html.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. lifted its stake in shares of Seres Therapeutics by 15.9% in the 1st quarter. JPMorgan Chase & Co. now owns 370,225 shares of the biotechnology company’s stock valued at $4,172,000 after purchasing an additional 50,860 shares during the period. Geode Capital Management LLC lifted its stake in shares of Seres Therapeutics by 5.8% in the 1st quarter. Geode Capital Management LLC now owns 166,325 shares of the biotechnology company’s stock valued at $1,874,000 after purchasing an additional 9,060 shares during the period. Goldman Sachs Group Inc. lifted its stake in shares of Seres Therapeutics by 24.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 44,418 shares of the biotechnology company’s stock valued at $501,000 after purchasing an additional 8,851 shares during the period. Citadel Advisors LLC lifted its stake in shares of Seres Therapeutics by 74.8% in the 1st quarter. Citadel Advisors LLC now owns 20,662 shares of the biotechnology company’s stock valued at $233,000 after purchasing an additional 8,841 shares during t

Other equities research analysts have also recently issued research reports about the company. BidaskClub cut Seres Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, August 11th. Cowen and Company reiterated a “buy” rating on shares of Seres Therapeutics in a report on Monday, October 2nd. Zacks Investment Research cut Seres Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, August 8th. HC Wainwright reiterated a “buy” rating and issued a $19.00 price objective (up previously from $15.00) on shares of Seres Therapeutics in a report on Friday, August 4th. Finally, Canaccord Genuity set a $20.00 price objective on Seres Therapeutics and gave the stock a “buy” rating in a report on Thursday, August 3rd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the stock. Seres Therapeutics presently has an average rating of “Buy” and an average price target of $17.50.

Shares of Seres Therapeutics (NASDAQ:MCRB) opened at 11.53 on Friday. The firm has a 50-day moving average price of $14.64 and a 200-day moving average price of $14.64. Seres Therapeutics has a one year low of $8.86 and a one year high of $17.42. The company’s market capitalization is $467.10 million.

Seres Therapeutics (NASDAQ:MCRB) last issued its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.10). The company had revenue of $3.00 million for the quarter, compared to analysts’ expectations of $3.00 million. Seres Therapeutics had a negative net margin of 441.38% and a negative return on equity of 80.21%. The company’s revenue was up .0% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.70) earnings per share. Equities analysts forecast that Seres Therapeutics will post ($2.55) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This piece of content was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this piece of content can be accessed at https://ledgergazette.com/2017/10/07/seres-therapeutics-inc-mcrb-receives-new-coverage-from-analysts-at-seaport-global-securities.html.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. lifted its stake in shares of Seres Therapeutics by 15.9% in the 1st quarter. JPMorgan Chase & Co. now owns 370,225 shares of the biotechnology company’s stock valued at $4,172,000 after purchasing an additional 50,860 shares during the period. Geode Capital Management LLC lifted its stake in shares of Seres Therapeutics by 5.8% in the 1st quarter. Geode Capital Management LLC now owns 166,325 shares of the biotechnology company’s stock valued at $1,874,000 after purchasing an additional 9,060 shares during the period. Goldman Sachs Group Inc. lifted its stake in shares of Seres Therapeutics by 24.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 44,418 shares of the biotechnology company’s stock valued at $501,000 after purchasing an additional 8,851 shares during the period. Citadel Advisors LLC lifted its stake in shares of Seres Therapeutics by 74.8% in the 1st quarter. Citadel Advisors LLC now owns 20,662 shares of the biotechnology company’s stock valued at $233,000 after purchasing an additional 8,841 shares during the period. Finally, DekaBank Deutsche Girozentrale purchased a new position in shares of Seres Therapeutics in the 2nd quarter valued at approximately $236,000. Institutional investors own 74.76% of the company’s stock.

About Seres Therapeutics

Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.

Analyst Recommendations for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply